Demonstrating Clinically Credible Evidence and Manufacturing Feasibility to Unlock Investment for Microbiome Therapeutics
4:00 pm - Tuesday 10th November 2026
- Establishing clear pathways to regulatory approval through comparisons to existing products and demonstrated improvements in efficacy and safety to satisfy investor due diligence
- Addressing unmet therapeutic needs while showing likelihood of success to build investor confidence in achieving viable returns on capital deployed
- Communicating manufacturing scalability and cost of goods considerations for complex live bacterial production systems to address investor concerns about production feasibility
